跳至主要内容
临床试验/NCT04060290
NCT04060290已完成不适用

Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.14 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2020年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,000
试验地点
14
主要终点
Percentage and severity of Participants With Adverse Events (AEs)

研究概览

简要总结

This is a multi-center, Prospective, observational study,to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population,and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • In patients with malignant tumor who have been treated with albumin-bound paclitaxel for the treatment.

排除标准

  • 未提供

结局指标

主要结局

Percentage and severity of Participants With Adverse Events (AEs)

时间窗: 28 days after the end of the last chemotherapy cycle

percentage and CTC AE(v5.0) of AEs

次要结局

  • Objective response rate (ORR) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)(From signing informed consent,assessed up to end of study (up to approximately 24months))
  • evaluate patients' quality of life by the European Cancer Research and Treatment Tissue Cancer Quality Core Questionnaire EORTCQLQ-C30(From signing informed consent,assessed up to end of study (up to approximately 24months))

研究者

发起方
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验